Table 1.
Characteristics of the Female Transplant Recipients
| #1 | #2 | Recipient #3 | #4 | #5 | |
|---|---|---|---|---|---|
| Characteristic | |||||
| Age at transplant (years) | 31 | 36 | 37 | 52 | 28 |
| Reason for transplant | CML chronic phase | MDS (RAEB) | AML CR1 | Aplastic anemia | CML chronic phase |
| Type of transplant | BM | PBSC | PBSC | PBSC | BM |
| Conditioning | Cy 120 | Cy 120 | Cy 120 | Cy 120, Flu 125, | Cy 120, AraC 500 |
| TBI 13 Gy | TBI 12 Gy | TBI 12 Gy | ATG 120 | TBI 5.5 Gy | |
| Time from transplant to salivary gland biopsy | 57 months | 50 months | 40 months | 13 months | 201 months |
| History of pregnancy | Never | Never | 1 daughter 2 miscarriages |
1 daughter 1 son |
Never |
| History of blood transfusion | Never | Yes | Yes | Yes | Yes |
| GVHD | COP | None | Liver | Skin, oral | Skin, oral |
| Active at time of biopsy | no | — | no | yes | yes |
| % of positive male cells in salivary gland | 1.09% | 0.95% | 0.65% | 0.92% | 1.44% |
| % of positive male cells in buccal mucosa | 11.3% | 2.4% | 12.7% | n/a | n/a |
AML CR1 indicates acute myelogenous leukemia in first complete remission; AraC, Cytarabine 500 mg/m2; ATG, antithymocyte globulin 120 mg/kg; BM, bone marrow transplant; CML, chronic myelogenous leukemia; COP, cryptogenic organizing pneumonia; Cy, Cyclophosphamide 120 mg/kg; Flu, Fludarabine 125 mg/m2; MDS (RAEB), myelodysplastic syndrome with excess of blasts; PBSC, peripheral blood stem cell transplant; TBI, total-body irradiation; GVHD, graft-versus-host disease.